A TB therapy based on NQO1 targeting in combination with current first-line antibiotics may contribute to more quickly decreasing the bacterial burden below the spontaneous mutation frequency, thus reducing the probability of developing antibiotic-resistant TB. Here, NQO1 is linked to tuberculosis.